Developer docs
API playgroundTry for free, no card

Search company profiles

Radyus Research

Full company profile

uuid0000y7u

Namestring
Radyus Research
Legal namestring
Radyus Research & Development, Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Radyus Research & Development, Inc. is an Atlanta-based, privately held professional services firm founded in 2019 that operates as an embedded R&D operating partner for VC- and PE-backed biotech companies. Rather than selling software or discrete CRO services, the company delivers a fully integrated Program Management Organization (PMO) that consolidates strategy, regulatory, CMC, nonclinical, clinical, and program management into a single accountable execution layer spanning preclinical through clinical proof of concept. Its service bundle comprises eight functional modules — Development Strategy & Indication Selection, Regulatory Pathway & Agency Engagement, CMC & Manufacturing Strategy, Nonclinical & Translational Planning, Clinical Development & Trial Operations, Program & Portfolio Management, Diligence & Asset Readiness, and Commercial & Exit Strategy — sold as one cohesive engagement rather than à la carte components.

The company's operating model relies on a curated global network of CROs, CDMOs, and specialist partners (including Southern Research, Dt&CRO, and Eurofins CDMO Alphora) to provide execution capacity without internal infrastructure build. Therapeutic area coverage spans oncology, immunology, CNS, and metabolic diseases. Go-to-market is enterprise field sales targeting executive leadership and boards of VC/PE-backed portfolio companies, with custom-quoted pricing structured around program scope, duration, and complexity (no public pricing). The customer base is segmented into three primary personas — PE-Backed Platforms, Venture Studios, and VC-Backed Biotech — each requiring portfolio-level discipline, capital efficiency, and credible execution under investor and regulatory scrutiny. Revenue mechanics are managed-services style, likely retainer or milestone-based, but no revenue figures are disclosed.

Radyus is led by Co-founder and CEO Marta New, PhD, MBA, President and COO Kelly R. Pitts, PhD, and Co-founder and Director Paul Tebbey, PhD, MBA, supported by functional heads across development, clinical operations, scientific operations, CMC/manufacturing, toxicology, and project management. The company is privately held with only $200,000 in disclosed funding (raised in February 2020), implying services revenue has funded operations. Recent strategic activity includes three named CRO/CDMO partnerships (2024-2025), a South Korea-U.S. cross-border channel via Dt&CRO, and a May 2026 leadership and brand expansion.

Short descriptiontext

Radyus Research is an Atlanta-based R&D operating partner that delivers a fully integrated PMO for VC- and PE-backed biotech companies, consolidating strategy, regulatory, CMC, nonclinical, clinical, and program management into one accountable execution layer from preclinical through clinical proof of concept.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAtlanta, United States
HQ citystring
Atlanta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biotech R&D services, drug development management, clinical program management, regulatory affairs consulting, pharmaceutical development operations
Industry3 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGACAC
Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biotech R&D Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1R&D Program Management Services
TypeManaged Services
Description

Full-service R&D operating partnership providing end-to-end drug development services from preclinical through clinical proof of concept. Revenue derived from professional services engagements with VC/PE-backed biotech companies, likely structured as retainer or milestone-based contracts.

radyusresearch.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Radyus Research provides a fully integrated Program Management Organization (PMO) service that plans, executes, and owns drug development end-to-end, from preclinical through clinical proof of concept. The offering bundles development strategy and indication selection, regulatory pathway and agency engagement, CMC and manufacturing strategy, nonclinical and translational planning, clinical development and trial operations, program and portfolio management, diligence and asset readiness, and commercial and exit strategy into a single accountable operating layer for VC/PE-backed biotech companies.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Radyus Research offers a single, unified service offering: a fully integrated R&D Program Management Organization (PMO) that serves as an embedded operating partner for VC/PE-backed biotech companies. The core PMO service integrates eight distinct functional modules—Development Strategy & Indication Selection, Regulatory Pathway & Agency Engagement, CMC & Manufacturing Strategy, Nonclinical & Translational Planning, Clinical Development & Trial Operations, Program & Portfolio Management, Diligence & Asset Readiness, and Commercial & Exit Strategy—into one cohesive execution engine. Rather than selling separate software products or modules, Radyus delivers its expertise as a bundled service, replacing fragmented vendor stacks with a single accountable operating layer that aligns regulatory and manufacturing strategy with preclinical and clinical execution from preclinical through clinical proof of concept.

Product and service1 record
1R&D Program Management Organization (PMO) Services
Categorycore product
Description

Fully integrated Program Management Organization service that plans, executes, and owns drug development end-to-end for VC/PE-backed biotech companies. Acts as an embedded R&D PMO combining strategy, regulatory, CMC, nonclinical, clinical, and program management into a single accountable execution engine.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-28
Description

Strategic partnership to accelerate and optimize drug development. Eurofins CDMO Alphora provides integrated manufacturing with high-quality CMC development and GMP production capabilities across early and mid-stage programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-07
Description

Joint partnership to pave the way for South Korean biotech companies into the U.S. market. Dt&CRO is a Korean-based CRO specializing in non-clinical and clinical studies across therapeutic areas, known for operational scale and execution quality.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-13
Description

Strategic partnership to propel life sciences commercialization. Southern Research provides preclinical CRO capabilities and specialized scientific platforms supporting nonclinical development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Curated network of Contract Development and Manufacturing Organizations providing integrated CMC planning and phase-appropriate manufacturing readiness.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Network of Clinical Research Organizations supporting nonclinical and clinical studies across therapeutic areas.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

IQVIA is the world's largest CRO with biotech-dedicated units and integrated clinical, regulatory and real-world services — the most scaled incumbent offering an end-to-end alternative to Radyus's PMO model.

TypeDirect peer
Description

Allucent is a mid-size CRO purpose-built for small and mid-cap biotechs with integrated clinical and regulatory services, closely paralleling Radyus's positioning as a specialized operating partner for emerging biotech rather than a full-scale broad CRO.

TypeOthers
Description

Eurofins CDMO is one of Radyus's named strategic partners for CMC and GMP manufacturing, making it a relevant ecosystem participant rather than a direct competitor — comparable because it is part of the curated execution network the PMO model relies on.

TypeDirect peer
Description

Worldwide Clinical Trials is a mid-size CRO focused on complex therapeutic areas and small/mid biotech sponsors, offering integrated clinical operations and program management that overlaps directly with Radyus's clinical and nonclinical execution scope.

TypeDirect peer
Description

Rho is a privately held CRO specifically focused on emerging biotech and complex clinical programs, with integrated data, regulatory and clinical operations services — a comparable mid-size, science-led operating partner.

TypeBroad incumbent
Description

Medpace is a mid-size full-service CRO with a strong biotech and venture-backed sponsor book and a reputation for full-service program execution — the closest publicly traded analog to Radyus's integrated PMO model.

TypeDirect peer
Description

ProPharma Group combines life sciences consulting with compliance, regulatory and clinical services for pharma and biotech, comparable to Radyus's bundled PMO-and-strategy delivery model for under-resourced biotech teams.

TypeBroad incumbent
Description

ICON is a top-tier global CRO with biotech-focused divisions and integrated clinical and laboratory services, competing for the same emerging-biotech program work Radyus targets.

TypeBroad incumbent
Description

Charles River is a major CRO/CDMO covering preclinical, CMC and clinical services across all sponsor sizes; its integrated early-stage development offering competes with Radyus's PMO coordination of preclinical and CMC work.

10Camargo Pharmaceutical Services
TypeDirect peer
Description

Camargo provides integrated drug development, regulatory strategy and 505(b)(2) services to small and mid-sized biopharma, mirroring Radyus's emphasis on regulatory pathway design and end-to-end program ownership for emerging biotech clients.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Radyus Research

Biotech R&D Servicesradyusresearch.com

Radyus Research is an Atlanta-based R&D operating partner that delivers a fully integrated PMO for VC- and PE-backed biotech companies, consolidating strategy, regulatory, CMC, nonclinical, clinical, and program management into one accountable execution layer from preclinical through clinical proof of concept.

What Radyus Research does

Radyus Research & Development, Inc. is an Atlanta-based, privately held professional services firm founded in 2019 that operates as an embedded R&D operating partner for VC- and PE-backed biotech companies. Rather than selling software or discrete CRO services, the company delivers a fully integrated Program Management Organization (PMO) that consolidates strategy, regulatory, CMC, nonclinical, clinical, and program management into a single accountable execution layer spanning preclinical through clinical proof of concept. Its service bundle comprises eight functional modules — Development Strategy & Indication Selection, Regulatory Pathway & Agency Engagement, CMC & Manufacturing Strategy, Nonclinical & Translational Planning, Clinical Development & Trial Operations, Program & Portfolio Management, Diligence & Asset Readiness, and Commercial & Exit Strategy — sold as one cohesive engagement rather than à la carte components.

The company's operating model relies on a curated global network of CROs, CDMOs, and specialist partners (including Southern Research, Dt&CRO, and Eurofins CDMO Alphora) to provide execution capacity without internal infrastructure build. Therapeutic area coverage spans oncology, immunology, CNS, and metabolic diseases. Go-to-market is enterprise field sales targeting executive leadership and boards of VC/PE-backed portfolio companies, with custom-quoted pricing structured around program scope, duration, and complexity (no public pricing). The customer base is segmented into three primary personas — PE-Backed Platforms, Venture Studios, and VC-Backed Biotech — each requiring portfolio-level discipline, capital efficiency, and credible execution under investor and regulatory scrutiny. Revenue mechanics are managed-services style, likely retainer or milestone-based, but no revenue figures are disclosed.

Radyus is led by Co-founder and CEO Marta New, PhD, MBA, President and COO Kelly R. Pitts, PhD, and Co-founder and Director Paul Tebbey, PhD, MBA, supported by functional heads across development, clinical operations, scientific operations, CMC/manufacturing, toxicology, and project management. The company is privately held with only $200,000 in disclosed funding (raised in February 2020), implying services revenue has funded operations. Recent strategic activity includes three named CRO/CDMO partnerships (2024-2025), a South Korea-U.S. cross-border channel via Dt&CRO, and a May 2026 leadership and brand expansion.

Radyus Research firmographics

Firmographics
Name
Radyus Research
Legal name
Radyus Research & Development, Inc.
Website
https://radyusresearch.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Radyus Research is an Atlanta-based R&D operating partner that delivers a fully integrated PMO for VC- and PE-backed biotech companies, consolidating strategy, regulatory, CMC, nonclinical, clinical, and program management into one accountable execution layer from preclinical through clinical proof of concept.
Ownership category
akta.pro rank

Radyus Research industry classification

Industry
Product category
Biotech R&D Services
NAICS
Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGACAC
Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts)

Keywords

  • Biotech R&D services
  • Drug development management
  • Clinical program management
  • Regulatory affairs consulting
  • Pharmaceutical development operations

Where Radyus Research is headquartered

Location

Headquarters

HQ city
Atlanta
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Radyus Research business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. R&D Program Management Services: Full-service R&D operating partnership providing end-to-end drug development services from preclinical through clinical proof of concept. Revenue derived from professional services engagements with VC/PE-backed biotech companies, likely structured as retainer or milestone-based contracts.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Radyus Research product offering

Product offering

Core offering

Radyus Research provides a fully integrated Program Management Organization (PMO) service that plans, executes, and owns drug development end-to-end, from preclinical through clinical proof of concept. The offering bundles development strategy and indication selection, regulatory pathway and agency engagement, CMC and manufacturing strategy, nonclinical and translational planning, clinical development and trial operations, program and portfolio management, diligence and asset readiness, and commercial and exit strategy into a single accountable operating layer for VC/PE-backed biotech companies.

Product overview

Radyus Research offers a single, unified service offering: a fully integrated R&D Program Management Organization (PMO) that serves as an embedded operating partner for VC/PE-backed biotech companies. The core PMO service integrates eight distinct functional modules—Development Strategy & Indication Selection, Regulatory Pathway & Agency Engagement, CMC & Manufacturing Strategy, Nonclinical & Translational Planning, Clinical Development & Trial Operations, Program & Portfolio Management, Diligence & Asset Readiness, and Commercial & Exit Strategy—into one cohesive execution engine. Rather than selling separate software products or modules, Radyus delivers its expertise as a bundled service, replacing fragmented vendor stacks with a single accountable operating layer that aligns regulatory and manufacturing strategy with preclinical and clinical execution from preclinical through clinical proof of concept.

Differentiator

Problem solved

Functional benefit

Products and services

  • R&D Program Management Organization (PMO) Services Fully integrated Program Management Organization service that plans, executes, and owns drug development end-to-end for VC/PE-backed biotech companies. Acts as an embedded R&D PMO combining strategy, regulatory, CMC, nonclinical, clinical, and program management into a single accountable execution engine.

Companies that use Radyus Research

Customer profile

Segments3 records

Ideal customer profiles3 records

Radyus Research technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Radyus Research partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Eurofins CDMO AlphoracoreStrategic or Co-development Partner · 28 May 2025Strategic partnership to accelerate and optimize drug development. Eurofins CDMO Alphora provides integrated manufacturing with high-quality CMC development and GMP production capabilities across early and mid-stage programs.
  • Dt&CROcoreStrategic or Co-development Partner · 7 May 2024Joint partnership to pave the way for South Korean biotech companies into the U.S. market. Dt&CRO is a Korean-based CRO specializing in non-clinical and clinical studies across therapeutic areas, known for operational scale and execution quality.
  • Southern ResearchcoreStrategic or Co-development Partner · 13 March 2024Strategic partnership to propel life sciences commercialization. Southern Research provides preclinical CRO capabilities and specialized scientific platforms supporting nonclinical development.
  • CDMO NetworkminorStrategic or Co-development PartnerCurated network of Contract Development and Manufacturing Organizations providing integrated CMC planning and phase-appropriate manufacturing readiness.
  • CRO NetworkminorStrategic or Co-development PartnerNetwork of Clinical Research Organizations supporting nonclinical and clinical studies across therapeutic areas.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Radyus Research competitors and assessment

Company assessment

Broad incumbents

  • IQVIA: IQVIA is the world's largest CRO with biotech-dedicated units and integrated clinical, regulatory and real-world services — the most scaled incumbent offering an end-to-end alternative to Radyus's PMO model.
  • Medpace: Medpace is a mid-size full-service CRO with a strong biotech and venture-backed sponsor book and a reputation for full-service program execution — the closest publicly traded analog to Radyus's integrated PMO model.
  • ICON plc: ICON is a top-tier global CRO with biotech-focused divisions and integrated clinical and laboratory services, competing for the same emerging-biotech program work Radyus targets.
  • Charles River Laboratories: Charles River is a major CRO/CDMO covering preclinical, CMC and clinical services across all sponsor sizes; its integrated early-stage development offering competes with Radyus's PMO coordination of preclinical and CMC work.

Direct peers

  • Allucent: Allucent is a mid-size CRO purpose-built for small and mid-cap biotechs with integrated clinical and regulatory services, closely paralleling Radyus's positioning as a specialized operating partner for emerging biotech rather than a full-scale broad CRO.
  • Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size CRO focused on complex therapeutic areas and small/mid biotech sponsors, offering integrated clinical operations and program management that overlaps directly with Radyus's clinical and nonclinical execution scope.
  • Rho: Rho is a privately held CRO specifically focused on emerging biotech and complex clinical programs, with integrated data, regulatory and clinical operations services — a comparable mid-size, science-led operating partner.
  • ProPharma Group: ProPharma Group combines life sciences consulting with compliance, regulatory and clinical services for pharma and biotech, comparable to Radyus's bundled PMO-and-strategy delivery model for under-resourced biotech teams.
  • Camargo Pharmaceutical Services: Camargo provides integrated drug development, regulatory strategy and 505(b)(2) services to small and mid-sized biopharma, mirroring Radyus's emphasis on regulatory pathway design and end-to-end program ownership for emerging biotech clients.

Others

  • Eurofins CDMO: Eurofins CDMO is one of Radyus's named strategic partners for CMC and GMP manufacturing, making it a relevant ecosystem participant rather than a direct competitor — comparable because it is part of the curated execution network the PMO model relies on.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

Radyus Research social profiles

Digital presence

Radyus Research financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Radyus Research leadership team

Management profile

Number of profiles

Profiles16 records

Radyus Research funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Radyus Research M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Radyus Research

What does Radyus Research do?

Radyus Research provides a fully integrated Program Management Organization (PMO) service that plans, executes, and owns drug development end-to-end, from preclinical through clinical proof of concept. The offering bundles development strategy and indication selection, regulatory pathway and agency engagement, CMC and manufacturing strategy, nonclinical and translational planning, clinical development and trial operations, program and portfolio management, diligence and asset readiness, and commercial and exit strategy into a single accountable operating layer for VC/PE-backed biotech companies.

Is Radyus Research a public or private company?

Radyus Research is a private company. It is classified as unknown and is currently operating.

When was Radyus Research founded?

Radyus Research was founded in 2019. It employs 11 to 50 people.

Where is Radyus Research based?

Radyus Research is headquartered in Atlanta, United States, in the North America region.

How does Radyus Research make money?

One revenue line is on record: R&D Program Management Services.

Who are Radyus Research's main competitors?

Broad incumbents on record are IQVIA, Medpace, ICON plc and Charles River Laboratories. Direct peers are Allucent, Worldwide Clinical Trials, Rho, ProPharma Group and Camargo Pharmaceutical Services. Eurofins CDMO is listed as an others.

Does Radyus Research have an API?

No public API is recorded for Radyus Research.

What industry is Radyus Research in?

Radyus Research's product category is Biotech R&D Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceRadyus Research & Development Expands Brand and Leadership Team to Scale PMO-Led Drug Development ModelRadyus announced it will operate under the name Radyus Research & Development, expanding into a full-lifecycle R&D PMO with integrated clinical operations. The company appointed Charlotte Chadwick as Head of Clinical Operations and Kelly R. Pitts as President and COO. The expansion aims to support growing client demand for integrated, end-to-end drug development.PR NewswireRadyus Research and Dt&CRO Join Forces to Pave Way for South Korean Biotech Companies into the U.S. MarketRadyus Research and Dt&CRO announced a partnership to help South Korean biotech companies enter the U.S. market, offering integrated drug development, regulatory strategy, IND filings, and clinical trial management. Radyus will use Dt&CRO for non-GLP and GLP laboratory testing for Asian clients. The collaboration aims to accelerate development and commercialization of breakthrough therapies.MorningstarRadyus Research Forges Strategic Partnership with Southern Research to Propel Life Sciences CommercializationRadyus Research and Southern Research announced a strategic partnership to combine preclinical services for life sciences commercialization. The collaboration aims to offer a one-stop solution for drug development, including consulting, project management, and laboratory testing. The partnership seeks to foster a thriving ecosystem for life sciences companies in the Southeast region.PR NewswireRadyus Research Forges Strategic Partnership with Southern Research to Propel Life Sciences CommercializationRadyus Research and Southern Research announced a strategic partnership to offer integrated preclinical services for life sciences commercialization in the Southeast. The collaboration combines Southern Research's 80-year drug discovery experience with Radyus Research's project management, aiming to provide a one-stop solution for clients.